United Therapeutics Corp
XMUN:UTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Economic Moat
United Therapeutics has a narrow economic moat
Patents covering key medicines and their delivery technology prevent rivals from freely copying parts of United Therapeutics’ treatments. For some Remodulin patients, changing treatment also means learning a different pump system and carefully managing an uninterrupted drug supply, making a cheaper rival less straightforward to adopt.
What protects United Therapeutics from competitors
Intangible Assets
United Therapeutics owns or licenses patents covering Tyvaso’s formulations, delivery technology and treatment methods, limiting how rivals can copy these products. Its successful patent case against Liquidia over treating lung-disease-related pulmonary hypertension provides concrete evidence that these rights can restrict competing uses.
High Switching Costs
Remodulin patients using the Remunity pump system receive device-specific training and depend on continuous drug delivery. This creates a practical switching hurdle: moving to a rival system can require retraining and a carefully coordinated transition rather than simply buying a cheaper medicine.
What could weaken United Therapeutics's moat
2 risks to watch
One for each source of the moat: what could happen and how it would weaken it
